Elekta announces that it has received one of its largest orders to date for nine Elekta Unity systems. Australian-headquartered GenesisCare, one of the largest providers of radiation therapy in the world, will install the units in Australia, Asia Pacific and Europe, improving global access to Elekta’s next generation radiotherapy platform. This order brings the total number of Unity systems ordered by GenesisCare to 10, including the purchase of a Unity system announced in 2018.
Elekta Unity combines a state-of-the-art 1.5T MRI scanner and a best-in-class 7MV linear accelerator, giving it the ability to reshape the radiation dose based on daily changes in shape, size and position of tumor and surrounding healthy anatomy. This groundbreaking technology enables accurate dose delivery with real-time visualization of the tumor so that doctors can better target cancers and minimize risk to surrounding tissue.
Dan Collins, CEO at GenesisCare, said: “This innovative technology represents a new era in radiotherapy. It will provide new hope for patients with types of cancer that have been challenging to treat, including pancreatic cancer, liver cancer, head and neck cancers, and other soft tissue tumor groups including prostate cancer. Our order for nine further Elekta Unity systems will increase access to this cutting-edge technology, as we focus on improving the life outcomes of people with cancer around the world.”
The agreement also extends the strategic partnership between GenesisCare and Elekta to include a program to advance the ongoing clinical development of adaptive therapy based on real-world evidence. Using GenesisCare’s global network, built on a backbone of Elekta’s oncology information systems, both organizations will work together to create standardized data repositories that advance adaptive therapy technologies and create a platform to assess the clinical value of radiotherapy.
Richard Hausmann, CEO at Elekta, said: “We share GenesisCare’s focus on patients. With this order, cancer patients – and those who treat them – will have greater access to MR-guided adaptive therapy, the most precise form of radiation treatment. In addition, to help realize our common long-term vision for radiotherapy, we are establishing an innovative partnership to generate and leverage real-world evidence that speaks to the needs of every stakeholder: device manufacturers, policy makers and, most importantly, patients and their advocates.”
The total value of the agreement is USD 58 million and will be booked in the first quarter of Elekta’s 2019/20 fiscal year. The first deliveries are scheduled for mid-2020.
For almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.